Corrigendum to “Review of trials currently testing treatment and prevention of COVID-19” [Clin Microbiol Infect 26.8 (2020) 988–998]

The authors regret that at the “Transparency declaration” (p. 997) of the published paper, the conflicts of interest were unintentionally incomplete.The following is the correct “Transparency declaration”: For Y.Y.: Co-Chair of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) and the coordinator of REsearch and ACTion targeting emerging infectious diseases (REACTing); Presentations at workshops and consultancy honoraria from Abbvie, Gilead, Merck, J&J, and ViiV Healthcare but not since 2017. For C.S.: Consultancy and research funding, Hycor Biomedical and Thermo Fisher Scientific; Consultancy, Bencard Allergie; Research Funding, Mead Johnson Nutrition. Supported by Universities Giessen and Marburg Lung Centre (UGMLC), the German Center for Lung Research, University Hospital Giessen and Marburg research funding according to article 2, section 3 cooperation agreement, and the Deutsche Forschungsgemeinschaft-funded-SFB 1021 (C04), -KFO 309 (P10), and SK 317/1-1 (Project number 428518790) as well as by the Foundation for Pathobiochemistry and Molecular Diagnostics. For FXL: Payment for development of educational presentations, Gilead Sciences, Inc. and MSD (Merck Sharp & Dohme); Travel/accommodations/meeting expenses, Astellas Pharma Inc., Eumedica Pharmaceuticals, MSD (Merck Sharp & Dohme). For PCF: Research funding, Doctorate scholarship by the State Scholarships Foundation (IKY), Partnership Agreement (PA) 2014-2020, co-financed by Greece and the European Union (European Social Fund - ESF) through the Operational Programme “Human Resources Development, Education and Lifelong Learning 2014-2020”. All grants are outside the submitted work. No external funding was received for this study.

The authors would like to apologise for any inconvenience caused.